Details

Published: 05 November 2025

Hits: 675

There’s blood on the hands of an industry that wraps itself in tie-dye and talks of “wellness.” Behind the carefully cultivated image of cannabis as a harmless plant medicine lies a devastating truth: young people who use marijuana face an 87% increased risk of attempting suicide. Not 8%. Not 17%. Eighty-seven percent.

These aren’t numbers conjured by prohibition-era scaremongering. They emerge from a rigorous systematic review and meta-analysis examining 500,408 participants across 18 studies. This is the kind of evidence that would trigger product recalls, congressional inquiries, and public health emergencies if we were discussing any substance without an army of lobbyists and cultural cheerleaders protecting its reputation.

Yet here we are, watching an entire generation’s mental health catastrophe unfold whilst cannabis culture shrugs, dissembles, and counts its profits.

When 87% Isn’t Enough to Matter

Let’s sit with that suicide attempt figure for a moment. An 87% increased risk amongst young cannabis users compared to non-users. Even after researchers adjusted for every conceivable confounding factor (socioeconomic status, family history, other substance use), the risk remained elevated at 80%. For suicidal ideation, the increase stands at 65%.

These are the kinds of risk elevations that pharmaceutical companies would be sued into oblivion for concealing. Yet somehow, when it comes to cannabis and youth suicide, we’re expected to smile politely whilst an industry built on wilful ignorance floods our communities with high-potency products specifically marketed to appeal to young people.

The cognitive dissonance is breathtaking. We claim to care about youth mental health. We wring our hands over rising suicide rates amongst 15 to 29-year-olds, the demographic for whom suicide remains the fourth leading cause of death globally. Then we turn around and normalise, commercialise, and celebrate a substance proven to dramatically increase their risk of suicidal behaviour.

Depression, Anxiety, and Convenient Amnesia

The suicide statistics are merely the most tragic endpoint of cannabis youth mental health harms. Young marijuana users show 51% higher odds of developing depression and 58% increased likelihood of experiencing anxiety. These aren’t subtle correlations requiring statistical gymnastics to detect. They’re blazing red flags visible from space.

Study after study, across multiple countries and methodologies, tells the same story: early cannabis initiation correlates with subsequent mental health deterioration. The earlier young people begin using, the earlier depressive symptoms emerge. As frequency increases (from occasional to weekly to daily use), mental health outcomes spiral downward with grim predictability.

But don’t expect cannabis culture to acknowledge any of this. Their playbook, borrowed wholesale from Big Tobacco’s greatest hits, involves manufacturing doubt, cherry-picking data, and dismissing inconvenient research as “reefer madness.” When confronted with evidence of harm, they pivot to legalisation talking points, criminal justice reform, or whatever rhetorical smokescreen proves most expedient.

The Neuroscience They’d Rather You Ignore

Here’s what actually happens when adolescents (whose brains won’t fully mature until their mid-twenties) consume cannabis regularly: THC disrupts cannabinoid receptor type 1 (CBR1), triggering a cascade of neurological interference. Nerve impulse transmission falters. Intraneuronal connectivity suffers. The production of neuronal growth factors essential for synapse formation gets disrupted during the most critical period of brain development.

Neuroimaging studies have documented grey matter loss in specific brain regions amongst chronic cannabis users. These are structural changes associated with psychiatric and mood disorders. This isn’t speculation. It’s observable, measurable damage to developing brains.

Yet the cannabis industry continues peddling its “natural” and “harmless” mythology, as though something being plant-derived renders it incapable of harm. By that logic, hemlock makes an excellent salad ingredient and belladonna belongs in your smoothie.

The Self-Medication Lie

When pressed about the risks linking cannabis and youth suicide, advocates often deploy the “self-medication” defence: vulnerable young people use marijuana to cope with pre-existing mental health challenges, they argue, creating a chicken-and-egg scenario that conveniently absolves cannabis of culpability.

Even if we accept this framing (and the evidence suggests it’s only part of the picture), it hardly exonerates the substance. What kind of “medicine” increases suicide attempt risk by 87%? What manner of “therapy” exacerbates the very conditions it purports to treat?

The self-medication narrative actually reveals cannabis culture’s profound cynicism. They’re essentially admitting that psychologically distressed teenagers and young adults are turning to their product, then shrugging when those same young people experience worsened outcomes. It’s the equivalent of selling alcohol to someone drowning and calling it a flotation device.

A Twenty-Billion-Dollar Lie

Global cannabis sales continue their meteoric rise, with legalisation spreading across Canada, multiple US states, Germany, Malta, Thailand, and South Africa. Consumption has surged 20% over the past decade. Marketing budgets rival those of major consumer brands. Product innovation (edibles, vapes, concentrates with THC levels our grandparents couldn’t have imagined) proceeds at breakneck pace.

And through it all, the industry maintains its pose of wounded innocence. According to them, they’re just providing what the people want. They’re correcting historical injustices, they insist. A safer alternative to alcohol is what they’re offering. Consumer choice is being respected.

What they’re actually doing is replicating every cynical strategy that allowed tobacco companies to hook generations of customers whilst denying the mounting evidence of harm. The difference is that cannabis has successfully cloaked itself in progressive politics and counterculture credibility, making it somehow gauche to point out that their products are destroying young people’s mental health and, in the most tragic cases, contributing to their deaths.

The Studies They Won’t Discuss

By 2021, 46% of countries identified cannabis as the predominant substance associated with drug abuse disorders. Thirty-four percent cited marijuana as the primary reason individuals sought treatment for substance abuse. These figures represent a global crisis hiding in plain sight.

Cannabis Use Disorder (CUD) rates are climbing, with adolescents proving particularly vulnerable. Those who develop CUD show even higher rates of depression, anxiety, and suicidal behaviour. It’s a vicious cycle that begins with “just trying it” and ends with grey matter loss and psychiatric disorders.

The research demonstrates clear dose-response relationships: more frequent cannabis consumption correlates with worse mental health outcomes. Daily users report intensified feelings of burdensomeness, thwarted belonging, and suicidal ideation. New consumption methods like vaping (marketed with the same sophisticated techniques that made Juul so devastatingly effective amongst teenagers) appear to amplify these risks.

Yet somehow, amidst this tsunami of evidence, cannabis culture has convinced itself and much of the public that marijuana is essentially harmless. It’s a marketing triumph and a public health catastrophe.

The Gender Gap They Ignore

Even the research landscape reveals telling gaps. Whilst most studies include mixed-gender samples, only a minority provide sex-disaggregated results. This matters enormously, given evidence that women with Cannabis Use Disorder exhibit higher prevalence of mood and anxiety disorders compared to men.

But conducting thorough, gender-specific research might reveal inconvenient truths. Better to maintain strategic ambiguity, continue the broad-brush reassurances, and avoid drilling down into the specific mechanisms of harm.

Profiting from Pandemic Trauma

The COVID-19 pandemic intensified mental health challenges amongst young people: daily disruptions, health anxieties, isolation, bereavement. In any sane response to this suffering, we’d be doing everything possible to protect vulnerable youth from substances that worsen mental health outcomes.

Instead, cannabis companies saw opportunity. Market expansion continued unabated. Product development accelerated. The push to normalise marijuana consumption amongst ever-younger demographics intensified.

When the dust settles on this era, when we finally acknowledge the full scope of cannabis youth mental health harms, we’ll look back with horror at how an industry was permitted to exploit a generation’s trauma for profit.

The Frequency Trap

The pattern is grimly consistent: occasional use leads to weekly use, weekly use escalates to daily use, and daily use correlates with the most severe mental health outcomes. Young people aren’t being told this. They’re being told cannabis is medicine, that it’s natural, that it’s safer than alcohol.

No one tells them that daily cannabis use intensifies feelings of hopelessness and social disconnection, the very psychological states that lead to suicidal crises. No one tells them that as THC potency increases, with today’s products vastly stronger than those from a decade ago, the psychiatric risks rise as well.

The cannabis industry knows all of this. They employ researchers, monitor studies, track trends. Their ignorance isn’t innocent. It’s calculated.

Beyond Doubt

The systematic review examining cannabis youth mental health outcomes encompassed over half a million participants. The methodology was rigorous. The findings were consistent across different study designs, countries, and time periods. This isn’t preliminary data requiring cautious interpretation. It’s evidence demanding urgent action.

Yet cannabis advocates continue their evidence-denying rampage, dismissing research that doesn’t support their narrative whilst trumpeting any study (however methodologically flawed) that suggests potential benefits. It’s the same playbook tobacco companies used for decades, the same cynical manipulation of scientific discourse in service of profit.

What We Owe Young People

Young people deserve honesty. They need adults who will prioritise their mental health and survival over cultural trends, political posturing, and corporate profits. We must also protect them from an industry that treats their developing brains as acceptable collateral damage in the pursuit of market share.

Most urgently, we owe them recognition of what the evidence actually shows: cannabis consumption amongst young people correlates with dramatically increased risks of depression, anxiety, suicidal ideation, and suicide attempts. The 87% increased risk of suicide attempts isn’t a statistical artifact or a coincidence requiring elaborate alternative explanations. It’s a screaming alarm that we’re choosing to ignore.

The Reckoning to Come

History won’t be kind to this moment. Future generations will look back and ask how we knew (how the evidence was this clear, this consistent, this damning) and did nothing. How we allowed an industry to market psychoactive substances to vulnerable young people whilst their lobbyists wrapped themselves in social justice rhetoric and their accountants counted the profits.

They’ll ask why, in an era supposedly concerned with youth mental health, we simultaneously normalised a substance proven to increase suicide risk. Who benefited from our collective amnesia and who paid the price will be another question demanding answers.

The answers will be uncomfortable. The cannabis industry benefited. So did cannabis culture. Politicians seeking easy tax revenue profited as well. Meanwhile, young people (an entire generation of young people) paid with their mental health and, in the most heartbreaking cases, with their lives.

Choosing Courage Over Comfort

Challenging cannabis orthodoxy invites predictable pushback. The accusations are as reliable as they are tedious: prohibitionist, alarmist, anti-science. Never mind that the science actually supports concerns about cannabis and youth suicide. Never mind that the systematic reviews and meta-analyses tell a consistent story of harm.

Cannabis culture has perfected the art of deflection. When confronted with evidence of psychiatric risks, they pivot to criminal justice reform. Studies showing increased suicide risk are dismissed with claims that correlation isn’t causation. Neuroimaging revealing structural brain changes? Researchers must be biased, they say.

It’s exhausting. It’s also beside the point.

The question isn’t whether cannabis should be legal for adults or whether cannabis prohibition was unjust. The question is whether we’re willing to acknowledge that young people who use marijuana face dramatically elevated mental health risks, including an 87% increased likelihood of attempting suicide.

The evidence says yes. Cannabis culture says look over there.

The Bodies Left Behind

Behind every statistic is a young person whose life was cut short or irrevocably altered. That 87% increased suicide attempt risk represents actual teenagers and young adults who didn’t need to die. The elevated rates of depression (51% higher odds) and anxiety (58% increased likelihood) translate to students who dropped out, careers that never launched, relationships that never formed.

These aren’t abstract numbers. They’re someone’s child, someone’s sibling, someone’s friend. They deserved better than to be sacrificed to an industry that values profit over human life and a culture that values being seen as progressive over protecting the vulnerable.

The systematic review examining cannabis and youth suicide provides evidence we can no longer ignore. Young cannabis users face dramatically elevated risks for depression, anxiety, suicidal ideation, and suicide attempts. The dose-response relationships are clear. The neurological mechanisms are documented. The consistency across studies is undeniable.

What remains unclear is whether we possess the courage to act upon this evidence or whether we’ll continue pretending everything is fine whilst young people die.

Cannabis culture wants us to believe this is complicated, that more research is needed, that we’re scapegoating a harmless plant. It’s not complicated. The research exists. And the plant is demonstrably not harmless when consumed by developing brains.

The Evidence Cannot Be Ignored

Studies published between 2013 and 2025, examining periods ranging from one month to 40 years, paint a consistent picture. Whether prospective longitudinal studies, retrospective analyses, or cross-sectional research, the pattern holds. The meta-analysis included data from countries including the United States, Canada, the United Kingdom, New Zealand, Australia, Ukraine, and Mexico. Different populations, different methodologies, same conclusion.

After adjustment for gender, age, ethnicity, living situation, education, employment, and other drug consumption, the elevated risks remained. This isn’t confounding. This isn’t coincidence. This is causation screaming to be acknowledged.

The odds ratios speak for themselves. Depression: 51% higher in cannabis users, 28% even after adjustment. Anxiety: 58% increased odds. Suicidal ideation: 50% to 65% higher depending on the model. Suicide attempts: 87% unadjusted, 80% adjusted.

These numbers represent individual human tragedies multiplied across hundreds of thousands of young lives. They represent families destroyed, potential unrealised, futures stolen. They represent the price we’re paying for allowing an industry to prioritise profits over the wellbeing of an entire generation.

The Industry’s Playbook

The cannabis industry has learned well from its predecessors. When tobacco companies faced mounting evidence of harm, they didn’t admit fault. Tobacco companies funded counter-research and emphasised personal choice. When confronted with evidence, they questioned the science, then delayed, deflected, and denied until the body count became impossible to ignore.

Cannabis companies are following the same script. Cannabis companies fund studies designed to find benefits and emphasise adult choice whilst their marketing clearly targets youth. When results don’t suit them, they question the methodology. Hiding behind progressive rhetoric, the industry continues building an addiction-for-profit empire.

The difference is that we’ve seen this playbook before. We know where it leads. We know how it ends. Yet somehow, we’re permitting the same tragedy to unfold with marijuana consumption amongst young people, wrapped in different packaging but delivering identical results: corporate profits built on human suffering.

What Honesty Demands

The evidence demands we abandon comfortable fictions about cannabis being harmless, natural, or therapeutic for young people. The systematic review encompassing over half a million participants presents findings too consistent to dismiss, too significant to downplay.

We need open, honest discussions about cannabis and youth suicide, without the spin of commercial interests or cultural agendas. Those in power should put young people’s wellbeing ahead of profit. Schools, parents, and communities must also share the plain facts about marijuana’s risks, especially its links to suicide and serious mental illness.

Most urgently, we need to question why, in an era supposedly concerned with youth mental health, we’re simultaneously normalising a substance that increases suicide attempt risk by 87%. The cognitive dissonance is staggering.

A Final Question

The only question left is: how many more young lives will we allow cannabis industry profits to claim before we finally say enough?

The research is unequivocal. Young cannabis users face 87% higher risk of suicide attempts. Young cannabis users experience 51% higher odds of depression and show a 58% greater likelihood of anxiety. Their rates of suicidal ideation rise by 65%, revealing just how severe the mental health risks truly are. These aren’t marginal increases. These are catastrophic elevations in harm.

Cannabis culture will continue manufacturing doubt. The industry will keep counting profits. Lobbyists will keep spinning narratives. But the evidence won’t change. The dead won’t come back. And history will record our choice: profits or young lives.

We know which one cannabis culture has chosen. The question is which one the rest of us will choose.

(Source: WRD News) 

Details

Published: 01 November 2025

Hits: 448

Key Points

Question  What is the size of the placebo response in cannabinoid trials for clinical pain, and is the magnitude of placebo response associated with media attention on the trials?

Findings:  This meta-analysis of 20 studies of 1459 individuals found a significant pain reduction in response to placebo in cannabinoid randomized clinical trials. Media attention was proportionally high, with a strong positive bias, yet not associated with the clinical outcomes.

Meaning:  These findings suggest that placebo has a significant association with pain reduction as seen in cannabinoid clinical trials, and the positive media attention may shape placebo responses in future trials.

Abstract

Importance:  Persistent pain is a common and disabling health problem that is often difficult to treat. There is an increasing interest in medicinal cannabis for treatment of persistent pain; however, the limited superiority of cannabinoids over placebo in clinical trials suggests that positive expectations may contribute to the improvements.

Objective:  To evaluate the size of placebo responses in randomized clinical trials in which cannabinoids were compared with placebo in the treatment of pain and to correlate these responses to objective estimates of media attention.

Main Outcomes and Measures:  Change in pain intensity from before to after treatment, measured as bias-corrected standardized mean difference (Hedges g).

Results:  Twenty studies, including 1459 individuals (mean [SD] age, 51 [7] years; age range, 33-62 years; 815 female [56%]), were included. Pain intensity was associated with a significant reduction in response to placebo, with a moderate to large effect size (mean [SE] Hedges g, 0.64 [0.13]; P < .001). Trials with low risk of bias had greater placebo responses (q₁ = 5.47; I² = 87.08; P = .02). The amount of media attention and dissemination linked to each trial was proportionally high, with a strong positive bias, but was not associated with the clinical outcomes.

Conclusions and Relevance:  Placebo contributes significantly to pain reduction seen in cannabinoid clinical trials. The positive media attention and wide dissemination may uphold high expectations and shape placebo responses in future trials, which has the potential to affect the outcome of clinical trials, regulatory decisions, clinical practice, and ultimately patient access to cannabinoids for pain relief. (Source: JAMA Open Network)

Also see

• Cannabis & Pain – Media Hype & the Placebo Reality?
• EXPOSE on CBD Part 2: Take Care with This Cannabinoid – The Problem of Pain
• CBD Not Recommended for Pain – Again (The placebo works)

Details

Published: 01 November 2025

Hits: 422

Key Takeaways 

• Broad temporal and population spectrum on cannabis use & mental health.
• Cannabis linked to depression, anxiety and suicidal tendencies in studies.
• Early cannabis use in youth leads to mental health issues in adulthood.
• Systematic review and meta-analysis updates cannabis mental health risks evidence.

Abstract: Cannabis is the most widely consumed illicit drug globally. In 2021, 46 % of countries identified cannabis as the predominant substance associated with drug abuse disorders, with 34 % indicating it as the primary cause for seeking treatment. Young individuals represent the largest consumer demographic, experiencing substantial negative health effects. Despite extensive research on its mental health impacts, many aspects remain unclear. This study examines cannabis use among young people including anxiety, depression, and suicidal behavior. Studies involving individuals aged 15–30 were included. Data sources included PubMed, Mendeley, Embase, WOS, CINAHL, and Scopus. After screening 6466 articles, 36 met the inclusion criteria, with 18 included in the meta-analysis. These studies were published between 2013 and 2025. The results indicated that the odds of depression were 51 % higher in young cannabis users (OR = 1.51, 95 %CI = 1.23–1.86), decreasing to 28 % after adjustment (aOR = 1.28, 95 %CI = 1.10–1.50). Anxiety showed a 58 % increase (OR = 1.58, 95 %CI = 1.15–2.15). For suicidal ideation, the increase ranged from 50 % in unadjusted models (OR = 1.50, 95 %CI = 1.05–2.14) to 65 % in adjusted models (aOR = 1.65 95 %CI = 1.40–1.93). Finally, the odds of suicide attempt were 87 % higher (OR = 1.87, 95 %CI = 1.25–2.80), remaining elevated at 80 % after adjustment (aOR = 1.80, 95 %CI = 1.30–2.49).

(Complete Research - Source: Science Direct )

Details

Published: 30 October 2025

Hits: 402

Unique Pharmacological Challenges

Unlike alcohol, which displays a relatively predictable concentration-response relationship, THC presents distinct challenges for measuring and predicting impairment. THC is highly fat-soluble, leading to unpredictable absorption, distribution, and elimination patterns that vary significantly among individuals and circumstances. Peak THC concentrations do not correlate well with the degree of behavioural impairment, meaning that blood levels alone cannot reliably indicate driving fitness.

Studies on marijuana use and driving impairment have shown that the level of THC measured in blood or oral fluid and the degree of impairment are not closely related. Peak THC levels can occur when low levels of impairment are measured, and high levels of impairment can be measured when THC levels are low. This disconnect occurs because the hydrophobic THC molecule rapidly leaves hydrophilic blood as THC distributes readily into the brain and fatty tissue. Studies have shown very low THC blood levels of 2-4 ng/ml within one to two hours of use, even while significant impairment persists.

The route of administration dramatically affects onset and duration of effects. If marijuana is ingested through edibles, the onset of impairing effects occurs more slowly and lasts longer compared to smoking. Oral THC may take two to three hours to reach peak blood levels, meaning that someone could be significantly impaired immediately after consumption while still registering extremely low blood concentrations. Conversely, smoked marijuana produces rapid onset of effects with peak impairment occurring relatively quickly.

Individual biological factors create wide variability in response to THC. Absorption, distribution, and elimination vary based on route and frequency of intake, THC dose, titration of dose when smoked or vaporised, and individual user characteristics including body composition, metabolism, and genetic factors. These factors affect not only the amount of marijuana intake and metabolism but also the degree of behavioural impairment exhibited by users. The lack of definitive knowledge to quantify a concentration-response relationship for marijuana may be in part due to typical differences in research methods, tasks, subjects, and dosing that have been used to date.

Lack of Awareness Among Users

Perhaps most disturbing is the evidence of widespread ignorance about cannabis-related driving risks. The Ohio data showed THC levels indicating very recent use, suggesting drivers felt no hesitation about operating vehicles while impaired. Research consistently shows a considerable proportion of cannabis users have driven after using the drug, often with little concern about the risks they pose to themselves and others. Many users underestimate or remain completely unaware of the visual impairment caused by cannabis.

Normalising cannabis use has reduced perceived risks in the minds of many users. Prevention professionals understand that legalisation of substances lowers an individual’s perception of risk, altering judgment about the likelihood of negative occurrences related to that substance. As jurisdictions expand marijuana legalisation, the perception that cannabis use is benign extends to assumptions about driving while impaired. According to the National Highway Traffic Safety Administration, there has been a 48% increase in nighttime drivers who tested positive for THC, the chemical responsible for marijuana’s psychological effects.

According to the Traffic Safety Culture Index, drivers who use both marijuana and alcohol were significantly more prone to driving under the influence of alcohol. They are more likely to speed, text, intentionally run red lights, and drive aggressively. In 2020, SAMHSA data showed that around 12.6 million people ages 16 and up drove after using drugs, with the vast majority of nearly 12 million under the influence of marijuana. These numbers reveal a catastrophic failure of public awareness and prevention efforts.

Mental and Visual Acuity Utterly Undone

Visual Impairment Without User Awareness

Recent breakthrough research has revealed a particularly dangerous phenomenon that should concern everyone who shares the road. Cannabis significantly impairs visual function, but users often remain completely unaware of this impairment. A comprehensive study analysing the effects of smoking cannabis on vision found significant adverse effects on static visual acuity, contrast sensitivity, stereoacuity, accommodative response, straylight, night-vision disturbances (halos), and pupil size. All these parameters showed statistically significant impairment after cannabis use.

The study’s findings on self-perceived visual quality revealed that about two-thirds of participants thought using cannabis impaired their vision. This means approximately one-third of users did not perceive their vision had worsened after using cannabis, despite measurable deterioration in multiple visual parameters. This lack of awareness creates dangerous false confidence in driving ability. Contrast sensitivity, specifically for the spatial frequency of 18 cycles per degree, was identified as the only visual parameter significantly associated with self-perceived visual quality.

Cannabis consumption has a negative effect on both visual function and driving performance. The impairment noted in driving performance could be substantially due to visual degradation, given that most of the integrated information for driving is captured by the visual system. The research found significant correlations between certain visual and driving performance parameters, particularly regarding driving stability. The results highlight the importance of parameters such as visual acuity, contrast sensitivity, and stereoacuity, which play key roles in maintaining the vehicle in the lane properly.

The researchers noted that their results suggest a considerable lack of awareness of the risks associated with cannabis use in driving, given that a considerable proportion of participants had driven after using cannabis. They emphasised the need for awareness-raising and information campaigns aimed at the citizens, and continued research providing adequate insights into how this drug affects both short-term and long-term vision and the ability to drive safely.

The “Medicinal Cannabis” Exemption: A Public Safety Risk

Currently, significant lobbying pressure exists to exempt “medicinal” cannabis users from drugged driving laws. Proponents argue that treating their prescribed medication differently from other pharmaceutical preparations creates unfairness in the legislation. Those using cannabis formulations believe they are unfairly penalised compared to users of other prescription medications. This proposal presents several critical problems that make it unacceptable from a public safety perspective.

The presence of THC as the psychotropic constituent of cannabis-based drugs impairs driving skills regardless of whether it was obtained through prescription or recreational channels. The source of THC is irrelevant to its impairing effects on the brain and body. Many properly vetted and approved prescribed pharmaceutical grade medications of various origins can create impairment via drowsiness, and slower reaction times this diminished state can bring. Consequently, these prescriptions come with clear warnings that driving while on this medicine is warned against.

However, THC-induced intoxication represents a fundamentally different state from simple drowsiness. Intoxication brings another level of diminished capacity to the driver. Along with the idiosyncratic nature of intoxicants including THC, the potential for multi-level public harms is markedly increased. Drowsiness can be one symptom of intoxication, but intoxication involves far more than drowsiness alone. The comprehensive impairment of cognitive function, motor control, visual processing, and judgment that accompanies THC intoxication cannot be compared to the side effects of typical prescription medications.

Law enforcement cannot determine the source of THC detected in a driver’s system. Supplementing and misuse of cannabis products will be made substantially easier if medicinal exemptions are created. The potential for intoxicated driving to be given a free pass on the basis of claiming medicinal use becomes an obvious loophole that will be exploited. Under the current Pharmaceutical Benefits Scheme in Australia, the TGA certifies only two THC-based preparations as medicines: Sativex and Marinol. Other proposed formulations have not been fully subjected to clinical double-blind, placebo-controlled trials and have not been given pharmaceutical status. Scientifically, these products are not medicines.

The Australian Therapeutic Goods Administration has allowed and actively promoted a new category for “medicinal cannabis,” exponentially increasing the number of THC-contained products. Making the now Category 4 and 5 non-clinically trialled products easier to access for prescribing purposes has substantially grown the potential for abuse. How will law enforcement distinguish between THC from a prescription and THC from illicit sources? The answer is they cannot, rendering enforcement of drugged driving laws nearly impossible if exemptions are granted.

Insufficient Wait Times

Evidence suggests that even conservative estimates of safe waiting periods prove inadequate for ensuring driving safety after cannabis use. Colorado’s Department of Public Health and Environment made recommendations around marijuana use and driving based on extensive evidence review. For less-than-weekly marijuana users, they concluded that waiting at least six hours after smoking or eight hours after eating or drinking marijuana allows time for impairment to resolve. However, these recommendations reveal a critical problem: someone using THC daily would never have a safe window to drive.

If a baseline is drawn to maximise safety at 24 hours, then someone using this psychotropic substance daily will not be permitted to drive with any degree of assured safety. Even a 12-hour waiting period presents clear issues for regular users. The rapid distribution of THC into fatty tissues, including the brain, means blood levels drop while impairment may persist. Research is lacking on marijuana and impairment in frequent marijuana users, making it impossible to establish truly safe waiting periods for this population.

Recent research showing visual impairment and driving performance deficits extending beyond perceived recovery times raises serious questions about any proposed safe waiting period. One study found that subjects perceived the impairing effects of THC to be eliminated before a measurable improvement in driving performance was seen. The most recent research found that most driving-related skills are predicted to recover within approximately five hours, with almost all within approximately seven hours of inhaling 20 mg THC. However, oral THC-induced impairment may take longer to subside, and these estimates assume single-use by occasional users.

Limited Pharmaceutical-Grade Options

The expansion of what qualifies as medicinal cannabis has created a system ripe for abuse. Under the Australian Pharmaceutical Benefits Scheme, the TGA certifies only two THC-based preparations as medicines: Sativex and Marinol. These products have undergone rigorous clinical trials and received pharmaceutical status based on scientific evidence. Other proposed formulations have not been fully subjected to clinical double-blind, placebo-controlled trials. In scientific terms, these products lack the evidence base to be classified as medicines.

The Australian Therapeutic Goods Administration now actively promotes a new category for medicinal cannabis, exponentially increasing the number of THC-containing products available. Making Category 4 and 5 non-clinically trialled products easier to access for prescribing purposes has substantially increased availability. The potential for abuse of this new opportunity to access cannabis legally has grown dramatically. Users can now obtain cannabis products through medical channels that have not been subjected to the rigorous testing required of traditional pharmaceuticals.

The distinction between pharmaceutical-grade medicines and these expanded cannabis products matters enormously for driving safety. Traditional medicines undergo extensive research to characterise their effects, appropriate dosing, side effects, and contraindications. Cannabis products entering the market under expanded medicinal frameworks lack this robust evidence base. Prescribers and users have limited guidance about appropriate use, and the products themselves vary widely in potency and composition.

The Need for Evidence-Based Policy

The evidence is overwhelming and consistent across multiple jurisdictions and research methodologies. Cannabis use significantly impairs driving ability and substantially increases crash risk. Any policy that would exempt cannabis users from drugged driving laws represents an unacceptable compromise of public safety, regardless of whether that use occurs under the banner of medicine or recreation.

Zero-tolerance laws must remain in place, keeping cannabis (THC) firmly within the prohibited substances category for driving. No medical exemptions should be granted, as the source of THC has no bearing on its impairing effects. Clear mandatory wait times must be established and enforced, with minimum periods of 24 hours or more between cannabis use and driving for those who use THC-containing products. These waiting periods need to account for the pharmacokinetic properties of THC and the mounting evidence showing that impairment persists long after blood levels have dropped.

Public education campaigns similar to those deployed against drunk driving need to be launched immediately. The success of Mothers Against Drunk Driving in transforming cultural attitudes about alcohol-impaired driving provides a proven model for addressing cannabis-impaired driving. These campaigns must counter the normalisation of cannabis use and clearly communicate the genuine risks of driving while impaired. They must also dismantle the widespread misconception that medicinal use somehow confers immunity from impairment, a notion as dangerous as the old belief that experienced drinkers could safely drive above legal alcohol limits.

Warning labels on THC-containing products require substantial strengthening. Current warnings about drowsiness fail to adequately communicate the full spectrum of impairment risks. Labels must clearly present crash data and explain the specific ways cannabis impairs driving, including effects on reaction time, visual processing, judgment, and motor control. Explicit prohibitions on driving after use need to be prominently displayed. The warnings should specify minimum waiting periods and acknowledge that regular users may face considerably longer periods before safe driving can resume.

Policymakers must actively resist the normalisation of cannabis use being promoted through industry-funded campaigns. The marijuana industry has employed slick, well-funded marketing to minimise perceived risks and maximise market penetration. These efforts directly undermine public safety by creating false impressions that cannabis use carries minimal consequences. Government messaging must counter these narratives with evidence-based information about real harms, including the documented increases in traffic fatalities following legalisation.

Law enforcement requires adequate training and resources for detecting and prosecuting drugged driving. Cannabis impairment presents unique detection challenges compared to alcohol, where breathalysers provide immediate roadside assessment tools. Officers need comprehensive training in recognising signs of THC impairment through standardised field sobriety tests and drug recognition protocols. Laboratory capacity must expand significantly to handle increased testing demand. Legal frameworks must support effective prosecution despite the pharmacokinetic complexities of THC, including the disconnect between blood levels and actual impairment that makes cases more challenging than traditional drunk driving prosecutions.

Conclusion

The journey to reduce drunk driving took decades of public education, legal reform, and cultural change. Society eventually reached consensus that operating a vehicle while impaired by alcohol posed unacceptable risk to public safety. That consensus translated into strict laws, rigorous enforcement, social stigma against drunk driving, and dramatic reductions in alcohol-related traffic fatalities. Cannabis-impaired driving demands similar commitment, but we cannot afford the same timeline. The evidence is already clear, the data already compelling, and the body count already mounting.

Cannabis consumption, whether labelled medicinal or recreational, has negative effects on visual function, cognitive processing, motor control, and driving performance. The impairment is real, measurable, and dangerous. The increase in crash fatalities following legalisation is documented across multiple jurisdictions including Washington, Colorado, Oregon, California, and Alaska. The public health crisis exists now, demanding immediate policy response.

Driving represents a privilege that comes with responsibilities to protect public safety. No therapeutic benefit of cannabis, real or perceived, justifies the risk of allowing impaired individuals to operate motor vehicles. Our communities worked too hard to address drunk driving to now enable a new generation of intoxicated drivers. Lessons learned from alcohol apply directly to cannabis. Impairment is impairment. Intoxication is intoxication. The specific substance matters less than the fundamental truth that diminished capacity behind the wheel kills people.

The data from Ohio, Colorado, Washington, Canada, and numerous other jurisdictions tell the same story with remarkable consistency. Cannabis and driving creates a deadly combination. Legalisation correlates with increased crash rates. Higher THC levels correlate with greater impairment and crash risk. Users frequently drive while impaired, often unaware of the full extent of their diminished capacity. The normalisation of cannabis use extends to dangerous acceptance of drugged driving.

Policymakers must listen to the evidence rather than industry lobbying. They must reject pressure to create medical exemptions that would gut drugged driving enforcement. They must prioritise the safety of all road users over the convenience of cannabis users. The alternative, measured in preventable deaths, catastrophic injuries, and families forever shattered by loss, is simply unacceptable. Every traffic fatality involving a THC-impaired driver represents a failure of policy and prevention that could have been avoided.

The Ohio data showing 40% of fatal crash drivers testing positive for THC should serve as a wake-up call. These deaths were preventable. These families could have been spared. These tragedies did not need to happen. Moving forward requires courage to enact and enforce policies that protect public safety even when those policies prove unpopular with cannabis advocates. The evidence demands action. The death toll demands response. The time for that response is now.

(Source: WRD News)